Ipamorelin vs Macimorelin
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: Repeated-dose GH secretagogue research requiring hormonal selectivity and no cortisol/prolactin conf vs. GH deficiency diagnosis with an FDA-approved oral reference standard.
Quick Answers
Which is better, Ipamorelin or Macimorelin?
Neither compound has a universal evidence advantage. Research distinction: Repeated-dose GH secretagogue research requiring hormonal selectivity and no cortisol/prolactin conf vs. GH deficiency diagnosis with an FDA-approved oral reference standard.
What is the key difference between Ipamorelin and Macimorelin?
Macimorelin is oral and approved only for single-dose diagnostic use; ipamorelin is injectable with the cleanest hormonal selectivity profile (no cortisol, prolactin, or LH effects) of any GHRP - different routes and intended use patterns.
Evidence Comparison
Macimorelin: FDA approved (2017), Phase 3 diagnostic validation (Garcia 2018). Ipamorelin: Phase 2 post-operative ileus trial (Helsinn), no FDA approval. Macimorelin has the regulatory advantage; ipamorelin has the selectivity advantage.
Evidence Context Favoring Ipamorelin
Repeated-dose GH secretagogue research requiring hormonal selectivity and no cortisol/prolactin confounding.
Evidence Context Favoring Macimorelin
GH deficiency diagnosis with an FDA-approved oral reference standard.
Side-by-Side Snapshot
| Evidence grade | Ipamorelin: Level B Macimorelin: Level A |
|---|---|
| Research status | Ipamorelin: Phase 2 Macimorelin: FDA Approved |
| Primary category | Ipamorelin: Growth Hormone Macimorelin: Growth Hormone |
| Cited studies | Ipamorelin: 3 Macimorelin: 2 |